Under a royalty monetization agreement finalized in December 2024 ... particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update ...

Under the terms of the royalty financing agreement with HCRx, GENFIT intends to monetize a portion of the royalty payments due under the Ipsen agreement. Today’s agreement with HCRx includes an ...

Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge ...

Pascal Prigent, CEO of GENFIT, commented: “This non-dilutive financial agreement is a pivotal step in strengthening our financial outlook, extending our cash runway beyond 2027. We are also ...

Under a royalty monetization agreement finalized in December 2024 ... particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these ...

Once determined, interested holders will sign bond repurchase agreements and GENFIT will convene the bondholders' meeting. If the bondholders approve the necessary amendments to the 2025 OCEANEs' ...

GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases (the “Company”), today announces that it has entered into a non ...

Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare ...